Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Administration of immune checkpoint inhibitors via elastomeric pump versus IV bag: patient preference and cost analysis
2021-000058-24Phase 4Active
- Sponsor
- Erasmus MC Cancer Institute
- Start
- May 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of nivolumab and pembrolizumab in Nonhematologic neoplasms, melanoma, renal cell carcinoma (RCC) and 2 more (2 arms), sponsored by Erasmus MC Cancer Institute. Primary endpoint: Patient preference for administration method. Started May 2021; status: active.
02
Drugs
03
Conditions
Nonhematologic neoplasmsmelanomarenal cell carcinoma (RCC)non-small cell lung cancer (NSCLC)head and neck cancer (HNC)
Beyond the preview
Go deeper on 2021-000058-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000058-24.